GSK Plc ADR (NYSE:GSK) has a beta value of 0.52 and has seen 1.46 million shares traded in the recent trading session. The company, currently valued at $76.93B, closed the recent trade at $5490000.0 per share which meant it gained $5489961.93 on the day or 1459854% during that session. The GSK stock price is 100.0% off its 52-week high price of $44.67 and 100.0% above the 52-week low of $31.72. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.37 million shares traded. The 3-month trading volume is 5.49 million shares.
The consensus among analysts is that GSK Plc ADR (GSK) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 8 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 1.16.
GSK Plc ADR (NYSE:GSK) trade information
Over the past 30 days, the shares of GSK Plc ADR (NYSE:GSK) have changed -1.44%. Short interest in the company has seen 16.67 million shares shorted with days to cover at 3.18.
Wall Street analysts have a consensus price target for the stock at $35.25, which means that the shares’ value could drop -15574368.09% from the levels at last check today.. The projected low price target is $35.25 while the price target rests at a high of $35.25. In that case, then, we find that the latest price level in today’s session is 100.0% off the targeted high while a plunge would see the stock lose 100.0% from the levels at last check today..
GSK Plc ADR (GSK) estimates and forecasts
The company’s shares have gained 10.97% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 2.74%.
6 analysts offering their estimates for the company have set an average revenue estimate of 7.92B for the current quarter. 6 have an estimated revenue figure of 8.23B for the next ending quarter. Year-ago sales stood 7.88B and 8.01B respectively for this quarter and the next, and analysts expect sales will grow by 0.46% for the current quarter and 2.74% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -11.63% over the past 5 years. Earnings growth for 2025 is a modest 10.64% while over the next 5 years, the company’s earnings are expected to increase by 9.83%.
GSK Dividends
GSK Plc ADR is expected to release its next earnings report on 2025-Apr-30 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.61 at a share yield of 4.23%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 4.77%.
GSK Plc ADR (NYSE:GSK)’s Major holders
Insiders own 0.06% of the company shares, while shares held by institutions stand at 18.33% with a share float percentage of 18.34%. Investors are also buoyed by the number of investors in a company, with GSK Plc ADR having a total of 986.0 institutions that hold shares in the company. The top two institutional holders are DODGE & COX with over 68.34 million shares worth more than $2.63 billion. As of 2024-06-30, DODGE & COX held 1.6753% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 26.78 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.03 billion and represent 0.6566% of shares outstanding.
